Skip to content

MMM · 3M CO

33 filings

10-K

MMM 10-K Annual Reports

3M CO - 33 annual reports

Filing record · 2016–202610-K1110-Q338-K187

2025
3M CO Annual Report, Year Ended Dec 31, 2025
3M Company's 2025 Form 10-K highlights a year marked by strategic divestitures, significant litigation settlements, and ongoing operational adjustments. The company completed the spin-off of its Health Care business (Solventum) in April 2024, continuing to report its historical financial results as discontinued operations. Despite a modest 1.5% increase in net sales to $24.9 billion, the company faced challenges impacting profitability, including increased costs related to significant litigation, specifically the PFAS-related New Jersey Settlement and updates to site remediation obligations. These factors, alongside transformation costs and dis-synergies from exiting PFAS manufacturing and the Solventum spin-off, contributed to a decrease in GAAP operating income margin to 18.6% and diluted EPS to $6.00. Operationally, the Safety and Industrial segment showed robust growth with a 3.9% sales increase and improved segment operating income margin. However, the Transportation and Electronics segment experienced a 1.3% sales decline, impacted by headwinds in PFAS-manufactured products and the automotive OEM business. The Consumer segment saw a slight 0.2% decrease in sales. The company continued to manage its capital structure prudently, repurchasing $3.3 billion of its stock and paying $1.6 billion in dividends, while also navigating significant cash outflows related to legal settlements, totaling $8.2 billion paid by the end of 2025 for PFAS and Combat Arms Earplugs settlements. The company ended the year with $5.9 billion in cash, cash equivalents, and marketable securities.
Feb 3, 2026
2024
3M CO Annual Report, Year Ended Dec 31, 2024
3M Company's 2024 10-K filing reveals a pivotal year marked by the significant separation of its Health Care business (Solventum) on April 1, 2024. This strategic move, while impacting the company's structure and historical reporting, positions 3M to focus on its three core continuing segments: Safety and Industrial, Transportation and Electronics, and Consumer. The company navigated a complex operating environment in 2024, influenced by global economic conditions, geopolitical tensions, and ongoing litigation settlements. Despite these challenges, 3M demonstrated resilience, with efforts to drive productivity, manage costs, and invest in innovation. The report highlights the company's commitment to shareholder returns through dividends and share repurchases, alongside strategic capital deployment. Key financial and operational considerations for investors include the ongoing impact of litigation settlements, particularly related to PFAS and Combat Arms Earplugs, which continue to represent significant liabilities and affect financial results. The company's strategic exit from PFAS manufacturing by the end of 2025 is a critical ongoing development. Investors should monitor segment performance, the success of restructuring initiatives, and the company's ability to manage its substantial legal and environmental liabilities while pursuing growth opportunities.
Feb 5, 2025
2023
3M CO Annual Report, Year Ended Dec 31, 2023
3M Company's 2023 10-K filing reveals a challenging year marked by significant litigation charges that resulted in a net loss for the period, contrasting with the prior year's net income. The company incurred substantial pre-tax charges totaling approximately $15.2 billion related to the Public Water Systems (PWS) Settlement and the Combat Arms Earplugs (CAE) Settlement. Operationally, 3M experienced a sales decline of 4.5% to $32.7 billion, with organic sales down 3.2%. All four business segments—Safety and Industrial, Transportation and Electronics, Health Care, and Consumer—saw declines in net sales. The company continues its strategic move to spin off its Health Care business, expected in the first half of 2024, which it believes will position both entities for future growth. Despite the operational challenges and legal headwinds, 3M maintained its commitment to returning capital to shareholders, with dividend increases and share repurchases. The company also provided an outlook for increased pension and postretirement expense in 2024.
Feb 7, 2024
2022
3M CO Annual Report, Year Ended Dec 31, 2022
3M Company's 2022 Form 10-K details a challenging year marked by significant legal charges and strategic restructuring, alongside ongoing operational impacts from global economic factors. The company reported substantial legal expenses totaling $2.3 billion, primarily related to the Combat Arms Earplugs litigation and environmental matters associated with PFAS, including a $0.8 billion pre-tax charge for exiting PFAS manufacturing. These factors significantly impacted profitability, with operating income down 11.3% year-over-year. Despite these headwinds, 3M executed strategic divestitures, including the split-off of its Food Safety business, and continued to invest in innovation and sustainability, with capital expenditures of $1.75 billion. The company is also advancing its plan to spin off its Health Care business into a separate public entity, a move expected to enhance shareholder value by creating two more focused companies. Geographically, the Americas region showed resilience with a 1.7% sales increase, while Asia Pacific and Europe experienced sales declines. Management is focused on navigating these complex challenges by managing costs, optimizing its portfolio, and investing in future growth drivers. Investors should monitor the progress of the Health Care spin-off and the resolution of major legal and environmental liabilities, particularly those related to PFAS and earplug litigation, as these will be key determinants of future financial performance.
Feb 8, 2023
2021
3M CO Annual Report, Year Ended Dec 31, 2021
3M Company (MMM) reported its full-year 2021 financial results in its 10-K filing, showcasing resilience and growth amidst supply chain challenges and global economic shifts. The diversified technology company, operating across Safety and Industrial, Transportation and Electronics, Health Care, and Consumer segments, experienced broad-based organic growth, with total sales increasing by 9.9% year-over-year, driven by an 8.8% organic sales increase. Despite increased raw material and logistics costs, the company managed to offset these pressures through higher selling prices and continued productivity efforts. The Health Care segment demonstrated particularly strong performance with a 20.1% increase in operating income. While the company navigated inflationary pressures and supply chain disruptions, including the impact of extreme weather events, it maintained a strong financial position. Net income attributable to 3M was $5.92 billion, and the company returned significant capital to shareholders through $2.2 billion in share repurchases and $3.4 billion in dividends. Management highlighted its commitment to investing in growth, productivity, and sustainability, with plans for increased capital spending in 2022. However, investors should remain aware of the ongoing risks, including potential impacts from global economic conditions, public health crises, foreign currency fluctuations, and significant legal and regulatory proceedings, particularly those related to fluorochemicals (PFAS) and product liability.
Feb 9, 2022
2020
3M CO Annual Report, Year Ended Dec 31, 2020
In 2020, 3M Company (MMM) demonstrated resilience, navigating the COVID-19 pandemic with a slight increase in net sales by 0.1% to $32.184 billion, while net income attributable to 3M increased by 18.4% to $5.384 billion, or $9.25 per diluted share. The company saw strong demand in personal safety products, including respirators, which significantly benefited sales amidst the pandemic. Despite these positive results, several segments experienced declines due to market weakness exacerbated by COVID-19, notably in oral care, advanced materials, and automotive/aerospace. The company continued to manage its portfolio, including the divestiture of its drug delivery business. Management focused on cost control and operational efficiencies, leading to an improvement in operating income margins. Key risks highlighted include ongoing legal and regulatory proceedings, particularly related to PFAS (per- and polyfluoroalkyl substances), and global economic uncertainties. 3M also maintained a strong liquidity position and continued its commitment to returning capital to shareholders through dividends.
Feb 4, 2021
2019
3M CO Annual Report, Year Ended Dec 31, 2019
3M Company's 2019 10-K filing reveals a challenging year marked by a decline in net sales and net income, largely attributed to softness in key end markets such as automotive and electronics, coupled with channel inventory adjustments, particularly in the Asia Pacific region. The company experienced impacts from restructuring actions taken in the second and fourth quarters to address lower sales volumes and realign its organizational structure for improved growth and efficiency. Despite these headwinds, the Health Care and Consumer segments demonstrated sales growth. The company continued its strategic acquisitions, notably Acelity Inc., to bolster its Health Care segment, and also divested certain non-core businesses. Significant litigation-related charges, particularly concerning PFAS matters, impacted results, leading management to provide "adjusted" non-GAAP financial measures to offer insights into underlying operational trends. Looking ahead, 3M highlighted its ongoing commitment to strategic capital deployment, including investments in R&D and complementary acquisitions, alongside returning cash to shareholders through dividends and share repurchases. The company's financial condition remains stable with strong operating cash flow, though increased debt levels were noted, primarily related to recent acquisitions and financing activities. Management anticipates continued focus on productivity improvements and navigating global economic and regulatory landscapes.
Feb 6, 2020
2018
3M CO Annual Report, Year Ended Dec 31, 2018
3M Company's 2018 10-K filing reveals a diversified global technology company with five core business segments: Industrial, Safety and Graphics, Health Care, Electronics and Energy, and Consumer. The company reported net sales of $32.765 billion for the year ended December 31, 2018, an increase from $31.657 billion in 2017. Diluted earnings per share were $8.89, up from $7.93 in the prior year, reflecting strong operational performance and the positive impact of the Tax Cuts and Jobs Act. The company demonstrated solid operating cash flow of $6.4 billion, supported by robust free cash flow generation, which it utilized for significant share repurchases ($4.9 billion) and dividend payments, marking its 61st consecutive year of dividend increases. Management highlighted organic sales growth across all segments, driven by innovation and market penetration, particularly in advanced materials, personal safety, and health care solutions. Despite facing raw material price inflation and foreign currency headwinds, 3M's strategic focus on productivity initiatives and portfolio management, including the divestiture of certain businesses like the Communication Markets Division, contributed to its financial results. The company remains committed to investing in R&D, with $1.821 billion allocated in 2018, to fuel future growth and maintain its competitive edge. Key risk factors include global economic conditions, foreign currency fluctuations, and competitive pressures, which the company actively manages through its diversified operations and financial strategies.
Feb 7, 2019
2017
3M CO Annual Report, Year Ended Dec 31, 2017
3M Company's 2017 10-K filing reveals a robust performance driven by broad-based organic growth across its five key business segments: Industrial, Safety and Graphics, Health Care, Electronics and Energy, and Consumer. While net sales saw a 5.1% increase year-over-year to $31.7 billion, operating income grew by 8.3% to $7.8 billion, demonstrating effective operational management and productivity improvements. Diluted earnings per share (EPS) were $7.93, a slight decrease from the prior year's $8.16, primarily due to a significant impact from the Tax Cuts and Jobs Act (TCJA) enacted in late 2017, which resulted in a one-time tax expense. Excluding this TCJA impact, EPS grew by a notable 12.4% on a reported basis. The company continued its strategic portfolio management, completing several acquisitions, notably Scott Safety, which strengthened its Safety and Graphics segment. Divestitures were also actively pursued to focus on core, higher-value businesses. 3M's financial position remains strong, supported by healthy operating cash flow of $6.2 billion and a commitment to returning capital to shareholders through dividends and share repurchases, including a 16% increase in the quarterly dividend. The company's diversified business model, global reach, and commitment to innovation position it well for continued growth.
Feb 8, 2018
2016
3M CO Annual Report, Year Ended Dec 31, 2016
3M Company's 2016 10-K filing highlights a year of modest sales growth despite unfavorable foreign currency translation impacts. The company reported net sales of $30.1 billion, a slight decrease of 0.5% year-over-year, with organic local-currency sales declining by 0.1%. This performance was driven by mixed segment results, with Health Care, Safety and Graphics, and Consumer segments showing organic growth, while Electronics and Energy experienced a significant decline. The company successfully managed its cost structure, leading to an increase in operating income margins to 24.0% from 22.9% in the prior year, primarily due to favorable selling prices, lower raw material costs, and reduced pension expenses. Financially, 3M demonstrated strong operating cash flow of $6.7 billion, supporting significant investments in capital expenditures ($1.4 billion) and robust shareholder returns through dividends ($2.7 billion paid) and share repurchases ($3.75 billion). The company's capital structure optimization continued with an increase in debt, leading to a debt-to-total-capital ratio of 53% at year-end. Despite a challenging global economic environment, 3M maintained its strong credit ratings and demonstrated solid financial flexibility.
Feb 9, 2017
2015
3M CO Annual Report, Year Ended Dec 31, 2015
3M Company's 2015 10-K filing reveals a robust, diversified technology company navigating a complex global landscape. Despite a 4.9% year-over-year decline in net sales to $30.3 billion, primarily impacted by foreign currency translation, the company demonstrated resilience with a slight increase in diluted earnings per share to $7.58. This performance was supported by strategic acquisitions in Safety & Graphics and Industrial segments, coupled with ongoing investments in research and development. The company's financial health remains strong, with significant operating cash flow generation and a prudent approach to capital structure optimization, including substantial share repurchases and dividend increases. Management highlighted a strategic focus on growth markets, innovation, and operational efficiency, while also addressing global economic uncertainties and competitive pressures. Key operational highlights for 2015 include positive organic local-currency sales growth in the Health Care, Consumer, and Safety & Graphics segments, demonstrating the broad-based strength of 3M's diverse portfolio. However, the Industrial and Electronics & Energy segments faced headwinds. The company proactively managed raw material costs, benefiting from declining oil prices. Looking ahead, 3M remains committed to returning capital to shareholders and investing in its businesses, positioning itself for continued innovation and growth in diverse end markets.
Feb 11, 2016
2014
3M CO Annual Report, Year Ended Dec 31, 2014
3M Company's 2014 10-K report details a year of solid performance, characterized by revenue growth and increased earnings per share, driven by strong organic sales across most business segments, particularly Health Care and Safety and Graphics. The company demonstrated effective management of operating expenses, leading to improved operating income margins. Strategic investments in business transformation, including ERP system implementation, are noted as impacting short-term margins but are expected to yield long-term efficiencies. 3M also continued its commitment to returning capital to shareholders through dividends, which increased by 20% for the first quarter of 2015, and substantial share repurchases, underscoring a focus on enhancing shareholder value. The company's diversified business model and global presence provided resilience against currency fluctuations and varying economic conditions.
Feb 12, 2015
2013
3M CO Annual Report, Year Ended Dec 31, 2013
3M Company's 2013 10-K report highlights a year of solid growth, with total sales reaching $30.9 billion, a 3.2% increase over 2012, driven by broad-based organic local-currency sales growth across its five business segments. The company demonstrated robust profitability, with net income attributable to 3M increasing by 6.3% to $4.66 billion, translating to diluted earnings per share of $6.72. This performance was supported by effective cost management, favorable raw material costs, and strategic price adjustments. 3M continued its commitment to shareholder returns through significant share repurchases totaling $5.21 billion and a 34.6% increase in its quarterly dividend, marking its 56th consecutive year of dividend increases. The company also strategically invested in its future through research and development spending, which increased by 4.9% to $1.72 billion, and through acquisitions that bolstered its Industrial and Health Care segments.
Feb 13, 2014
2012
3M CO Annual Report, Year Ended Dec 31, 2012
3M Company's 2012 Form 10-K filing showcases a stable year with net sales of $29.9 billion, a slight increase of 1.0% over 2011. Net income attributable to 3M was $4.44 billion, or $6.32 per diluted share, representing a 6.0% increase on a per-share basis. The company demonstrated resilience despite a challenging global economic environment and significant currency headwinds, with organic local-currency sales growing 2.6%. The company continued its strategic focus on innovation and market presence, highlighted by acquisitions in key growth areas and an announcement to realign into five business groups effective in 2013. 3M maintained strong financial health, evidenced by robust operating cash flow and a consistent dividend payout, signaling confidence in its diversified business model and future prospects.
Feb 14, 2013
2011
3M CO Annual Report, Year Ended Dec 31, 2011
3M's fiscal 2011 10-K shows a company that grew sales 11.1% to $29.6 billion, with net income attributable to 3M rising 4.8% to $4.283 billion and diluted EPS up 5.8% to $5.96. Growth was led by Industrial and Transportation (+19.5%), Safety, Security and Protection Services (+15.2%) and Health Care (+11.5%), while Display and Graphics fell 5.4% on weak LCD TV optical film demand. Organic local-currency growth was 8.0% including acquisitions, and currency added 3.1 points. Operating margin slipped to 20.9% from 22.2% in 2010, largely because of higher cost of sales, pension expense and SG&A. Operating cash flow was $5.3 billion and free cash flow was $3.9 billion, after capital spending of $1.4 billion. The company returned cash through $2.7 billion of buybacks and $1.555 billion of dividends, and it raised the 2012 dividend 7.3%, the 54th consecutive annual increase. The balance sheet remains strong, with $4.6 billion of cash and marketable securities against $5.2 billion of debt, a 25% debt-to-capital ratio, and AA-/Aa2 credit ratings. Pension funding is a notable pressure point: the plans were 82% funded at year-end after a 1.08-point drop in the U.S. discount rate, which added about $2.4 billion to long-term liabilities and reduced equity by about $1.6 billion. Management expects $800 million to $1 billion of 2012 pension contributions and a roughly 9-cent per-share headwind from higher pension expense, plus a higher expected 2012 tax rate of about 29.5%. Management also announced CEO succession, with Inge Thulin set to replace George Buckley effective February 24, 2012, and a pending $550 million acquisition of Avery Dennison's Office and Consumer Products business.
Feb 16, 2012
2010
3M CO Annual Report, Year Ended Dec 31, 2010
3M's fiscal 2010 10-K shows a strong rebound year: record net sales of $26.7 billion (up 15.3% from $23.1 billion in 2009), with local-currency growth of 14.4% led by Electro and Communications, Display and Graphics, and Industrial and Transportation. Diluted EPS rose 24.6% to $5.63, and operating margin expanded to 22.2% from 20.8%. Growth was broad-based, with organic volume up 13.7% and all six business segments posting positive organic volume growth, though part of the 2009 comparison was depressed by restructuring charges (about $194 million pre-tax) that did not recur in 2010. Cash generation and balance sheet strength remained solid. Operating cash flow was $5.2 billion and free cash flow was $4.1 billion, against dividends of $1.5 billion. Net debt fell to $434 million from $1.1 billion, and the debt-to-total-capital ratio dropped to 25% from 30%. Management signaled continued investment, with about $1.8 billion spent on acquisitions (including Arizant, Cogent and Attenti in Q4), a 4.8% dividend increase to $2.20 annualized, and a new $7.0 billion share repurchase authorization. Guidance for 2011 calls for sales growth of 10% or more, with a higher expected tax rate (about 29.5%) and pension expense rising by roughly 22 cents per share. Key risks flagged in the filing include a two-thirds international revenue mix exposed to currency swings, ongoing respirator mask/asbestos and PFC environmental litigation, a Department of Justice and SEC investigation into the Turkish subsidiary, and a pending Meda AB claim of at least $200 million. Investors should weigh the strong 2010 earnings momentum against these contingent liabilities and the pressure from rising pension and tax costs in 2011.
Feb 16, 2011
2009
3M CO Annual Report, Year Ended Dec 31, 2009
3M's 2009 annual report shows a company navigating a severe global downturn with resilience. Full-year net sales fell 8.5% to $23.1 billion and organic volumes declined 9.5%, yet operating margin held near 20.8% (versus 20.6% in 2008) thanks to aggressive cost restructuring, roughly 400 million dollars of 2009 savings, and a vacation-policy change that added over $100 million to operating income. Net income attributable to 3M was $3.193 billion, or $4.52 per diluted share, down from $4.89 in 2008. Fourth-quarter sales grew 11.1% year-on-year with all segments and major regions improving, suggesting the trough may have passed. Management reduced headcount by roughly 6,400 positions since early 2008 and cut capital spending to $903 million from $1.471 billion, while maintaining $1.3 billion in R&D. Balance sheet strength is a key investor takeaway. Operating cash flow rose to $4.9 billion, net debt fell to $1.1 billion from $4.1 billion a year earlier, and the debt-to-total-capital ratio dropped to 30% from 39%. 3M holds AA- (S&P) and Aa2 (Moody's) ratings with stable outlooks, and the share repurchase program ($2.6 billion remaining) was suspended since late 2008 but remains available. The Board raised the 2010 quarterly dividend 2.9% to $0.525, marking the 52nd consecutive annual increase. Risks flagged in the filing include exposure to global economic conditions (about 63% of revenue from outside the U.S.), U.S. dollar strength, the expiration of the UK passport contract in October 2010, a potential loss of share in optical film as patents expire, a DOJ/SEC investigation into the Turkish subsidiary, and ongoing respirator/asbestos and PFC-related litigation and environmental liabilities. Management expects 2010 pension expense to rise by about $130 million pre-tax and plans $500 to $700 million in pension contributions.
Feb 16, 2010
2008
3M CO Annual Report, Year Ended Dec 31, 2008
3M's fiscal 2008 10-K shows a company that grew reported sales 3.3% to a record $25.3 billion, but the results mask a sharp fourth-quarter downturn. Local-currency sales grew only 1.4% for the year, with acquisitions (notably Aearo, bought in April 2008 for roughly $1.2 billion including assumed debt) contributing 3.3 points. Fourth-quarter sales fell 11.2%, and net income of $536 million was hit by $219 million of pre-tax restructuring and exit charges. Full-year net income fell 15.5% to $3.46 billion, or $4.89 per diluted share, versus $5.60 in 2007, which had benefited from large pharmaceutical divestiture gains. Excluding special items, underlying performance was far less dramatic than the headline decline suggests. The balance sheet weakened in ways investors should note. Total debt rose to $6.7 billion from $4.9 billion, and net debt more than doubled to $4.1 billion. The debt-to-capital ratio reached 40% versus 30% a year earlier. Management suspended share repurchases, cut 2009 capital spending by more than 30%, and planned for year-on-year declines in organic volume, margins, and EPS in 2009. Pension funded status fell from 100% to 85%, driving a $2.3 billion after-tax reduction in equity. Management still characterized the company's credit ratings (AA from S&P, Aa1 from Moody's with a negative outlook) and liquidity as strong. Dividends were nonetheless raised 2% for 2009, extending a 51-year streak. The main risks are a weak global industrial and consumer demand backdrop, currency headwinds from a strong U.S. dollar (about 64% of revenue is international), and contingent liabilities. These include respirator/asbestos claims with a $193 million insurance receivable, PFC-related environmental reserves of $137 million, and pending litigation. The 2008 restructuring program eliminated about 3,500 positions and is expected to save $250 to $300 million in 2009, but the filing gives no firm guidance beyond directional expectations for the year ahead.
Feb 17, 2009
2007
3M CO Annual Report, Year Ended Dec 31, 2007
3M's fiscal 2007 10-K shows record results, but with a significant one-time boost. Net sales rose 6.7% to $24.462 billion and net income rose 6.4% to $4.096 billion, or $5.60 per diluted share. Operating income grew 8.7% to $6.193 billion. Those reported figures include roughly $681 million of net gains (about $0.62 per diluted share after tax), mainly from the sale of the branded pharmaceuticals business in Europe and the Opticom/Canoga businesses, partly offset by environmental charges, restructuring and other exit costs. Excluding these items, management characterizes underlying operating income margins as similar to 2006. Underlying local-currency sales growth was 7.3%, with organic growth of 4.9%, acquisitions adding 2.4%, and divestitures reducing growth by 3.8%. Results were led by Safety, Security and Protection Services and Health Care, while Display and Graphics faced pricing and attachment-rate pressure in LCD monitors and TVs. Capital allocation was shareholder-focused. 3M returned about $4.6 billion through buybacks ($3.2 billion) and dividends ($1.38 billion), and the board authorized up to $7.0 billion of repurchases through February 2009, with about $4.1 billion remaining. The quarterly dividend was raised 4.2% to $0.50 for 2008, the 50th consecutive annual increase. Balance sheet leverage increased: total debt rose to $4.92 billion, and the debt-to-capital ratio reached 30% from 26%. Cash and marketable securities were about $3 billion. The company retains an AA (S&P) and Aa1 (Moody's, negative outlook) rating. Looking ahead, 3M expects 2008 capital expenditures of $1.3 to $1.4 billion, a pending acquisition of Aearo Holding Corp. for about $1.2 billion, and continued pressure on Display and Graphics margins. Raw material costs for metals, wood pulp and oil-derived inputs are expected to remain high into early 2008. Key risks include 63% of revenue coming from outside the U.S., respirator/asbestos litigation (about 8,750 claimants at year-end, down from about 17,700), and PFOA/PFOS environmental liabilities, which were increased by $121 million in Q1 2007 plus $13 million in Q2.
Feb 15, 2008
2006
3M CO Annual Report, Year Ended Dec 31, 2006
3M Company's 2006 Annual Report (Form 10-K) highlights a year of strong performance, with record net sales of $22.92 billion and record net income of $3.85 billion. This robust financial performance was driven by broad-based sales growth across all six business segments, bolstered by strategic acquisitions and consistent R&D investment. A significant event during the year was the sale of 3M's global branded pharmaceuticals business, which contributed $1.074 billion in pre-tax gains. While this divestiture streamlines the company's portfolio, it will impact year-over-year comparability in future periods. The company continued its commitment to shareholder returns through substantial share repurchases and a consistent history of dividend increases, underscoring its financial strength and commitment to shareholder value. Looking ahead, 3M plans to increase investments in R&D and capital expenditures to fuel future growth, focusing on core business reinvestment, emerging business opportunities, international expansion, and strategic acquisitions in high-growth industries. The company's diversified business model, global reach, and focus on innovation position it well for continued success.
Feb 26, 2007
2005
3M CO Annual Report, Year Ended Dec 31, 2005
3M Company's fiscal 2005 10-K shows a record year: net sales rose 5.8% to $21.167 billion, net income reached a record $3.199 billion ($4.12 per diluted share, versus $3.75 in 2004), and operating income grew 9.4% to $5.009 billion, lifting operating margin to 23.7% from 22.9%. Growth was broad-based, with all seven business segments posting positive local-currency sales growth. Industrial (boosted by the August 2005 CUNO acquisition, which contributed 5.1 points of segment growth) and Electro and Communications (operating income up 35.4%) stood out, while Display and Graphics sales growth was held back by declines in CRT rear-projection lens systems and the commercial videotape phase-out. Core local-currency sales grew 4.1%, and pricing was a modest contributor at 0.6%. Capital allocation was shareholder-focused. 3M returned about $3.6 billion to shareholders in 2005 through $2.377 billion of share repurchases and $1.286 billion of dividends, and raised its quarterly dividend 16.7% during 2005 (47th consecutive annual increase). In February 2006 the board raised the quarterly dividend another 9.5% to $0.46 and authorized up to $2.0 billion of new buybacks through February 2007. Free cash flow was solid at roughly $3.3 billion (operating cash flow of $4.258 billion less $943 million of capex), though operating cash flow was flat versus 2004 and cash fell to $1.072 billion after the $1.36 billion CUNO purchase. Total debt declined to $2.381 billion, and debt to total capital fell to about 19%, supported by AA/Aa1 credit ratings. The filing also flags several items to watch. Management expects declines in personal care and branded pharmaceuticals (including Aldara, whose sales fell short of expectations) to persist through 2006, and a generic Metrogel-Vaginal substitute is expected in mid-2006. The 2006 outlook calls for higher R&D and capital spending (about $1.1 billion), and the adoption of SFAS 123R will reduce 2006 EPS by roughly $0.16. Legal exposures remain material: the respirator mask/asbestos docket of about 48,600 claimants carries $210 million in reserves against $447 million of insurance receivables, and the company faces PFOA/PFOS regulatory scrutiny and class actions. Roughly 60% of revenue comes from outside the United States, which creates currency sensitivity.
Feb 21, 2006
2004
3M CO Annual Report, Year Ended Dec 31, 2004
3M's 2004 Form 10-K shows a record year: net sales rose 9.8% to $20.011 billion, operating income grew 23.3% to $4.578 billion (22.9% margin, up from 20.4%), and net income reached $2.990 billion, or $3.75 per diluted share, versus $3.02 in 2003. Management attributes the gains to core volume growth of 6.2%, roughly $400 million of annual benefit from corporate initiatives (Six Sigma, Global Sourcing Effectiveness, 3M Acceleration, eProductivity), and a weaker U.S. dollar that boosted operating income by an estimated $286 million. Display and Graphics (optical films for flat-panel displays) was the standout segment, with 10.4% local-currency sales growth and a 27.8% increase in operating income. Growth was broad-based, with all seven segments contributing to sales growth. Balance sheet and cash flow strengthened considerably. Operating cash flow was $4.282 billion, and net debt fell to $64 million from $1.101 billion a year earlier, with cash of $2.757 billion. Total debt was $2.821 billion, about 21% of total capital. The company returned roughly $2.9 billion to shareholders through buybacks and dividends, and the Board authorized up to $2.0 billion in repurchases for January 2005 through January 2006. The dividend was raised to $0.42 per quarter, the 47th consecutive annual increase. The main investor risk is legal exposure. The respirator mask/asbestos reserve was increased by $40 million to $248 million, against $464 million of insurance receivables. Breast implant insurance receivables of $278 million depend on insurer payments that remain uncertain. The company faces a proposed settlement of indirect-purchaser tape antitrust claims, which management says is not material, plus PFOA/PFOS environmental reviews and a pending West Virginia silicosis suit. Management states that these matters would not have a material adverse effect on consolidated financial position, but future charges could affect results in a given period.
Feb 24, 2005
2003
3M CO Annual Report, Year Ended Dec 31, 2003
3M Company's 2003 Form 10-K report showcases a strong financial performance with record net sales of $18.232 billion and net income of $2.403 billion, representing a significant increase from the previous year. This growth was driven by broad-based performance across most of its seven business segments, with notable strength in Display and Graphics and Safety, Security and Protection Services. The company also emphasized its commitment to innovation and efficiency through ongoing corporate initiatives like Six Sigma and strategic acquisitions, which contributed to improved operating income and cash flow. Despite challenging economic conditions, 3M demonstrated resilience and a clear path towards sustainable growth, supported by a robust balance sheet and strong credit ratings.
Mar 2, 2004
2002
3M CO Annual Report, Year Ended Dec 31, 2002
3M Company's 2002 10-K filing reveals a year of robust performance, with net sales reaching $16.332 billion, a 1.7% increase year-over-year, driven by core volume growth and strategic acquisitions. The company reported net income of $1.974 billion, or $4.99 per diluted share, a significant improvement from the prior year, partly due to the cessation of goodwill amortization. Despite facing economic headwinds, 3M demonstrated strong operational efficiency, with operating income as a percentage of sales increasing notably. The company continued its commitment to innovation, investing heavily in research and development, and further diversified its portfolio through strategic acquisitions, notably Corning Precision Lens, Inc. The filing also details ongoing efforts to streamline operations through a restructuring plan, which, while incurring charges, is expected to yield long-term cost efficiencies.
Mar 10, 2003
1999
3M CO Annual Report, Year Ended Dec 31, 1999
3M's fiscal 1999 10-K shows a company that delivered higher earnings on slightly higher sales. Net sales rose 4.3% to $15.659 billion (volume up 5%, with a stronger U.S. dollar trimming about 1%). Operating income reached $2.956 billion, and net income rose to $1.763 billion, or $4.34 per diluted share, versus $2.88 in 1998 (which included a large restructuring charge). Excluding non-recurring items, diluted EPS was $4.21, up 12.6% from the prior year's comparable figure, and return on invested capital improved to 18.6%. Operating cash flow was strong at $3.038 billion, and total debt fell to $2.610 billion from $3.106 billion, with debt at 29% of total capital versus 34% a year earlier. The company also raised its quarterly dividend to 58 cents, marking the 42nd consecutive year of increases. The main investor overhang is the breast implant litigation. 3M has accrued about $1.2 billion in estimated probable liabilities against $1.114 billion already paid, leaving $86 million accrued, and it carries $622 million in insurance receivables that are substantially contested by carriers. A Minnesota insurance coverage trial was expected to reach a verdict around February 2000. Management believes the coverage outcome will be favorable and that further charges, if any, would not be materially adverse to financial position, though they could hit a given quarter's net income. Separately, a $73 million charge was taken for the LePage's antitrust verdict, which management expects to be overturned. Looking ahead, 3M guides to 2000 worldwide local-currency sales growth of 6 to 7 percent, driven mainly by volume, and expects solid profit growth. Restructuring from 1998 is substantially complete and is expected to yield about $250 million in annual pre-tax savings. Capital spending is projected at $1.0 to $1.1 billion, and the company is pursuing acquisitions including Quante AG in telecom. Key watch items for investors are the insurance litigation outcome, the pace of the 2000 volume recovery in Asia and Latin America, and price pressure in the Electro and Communications segment.
Feb 18, 2000
1998
3M CO Annual Report, Year Ended Dec 31, 1998
3M's 1998 10-K shows a year of strain: net sales were essentially flat at $15.02 billion (vs. $15.07 billion in 1997), with currency translation cutting sales roughly 3 percent and Asian and Latin American economic weakness weighing on volumes. Reported net income fell to $1.175 billion, or $2.88 per diluted share, from $2.121 billion ($5.06) in 1997, which included a large $803 million divestiture gain on National Advertising Company. Excluding the 1998 restructuring charge ($493 million pre-tax), the extraordinary debt-refinancing loss, and the 1997 gain, earnings per diluted share declined about 3.6 percent to $3.74 from $3.88. Operating margin excluding restructuring fell to 16.9 percent from 17.7 percent, and return on invested capital dropped to 15.9 percent. Management is taking action: a restructuring plan will eliminate about 4,500 net positions by year-end 1999 and is expected to yield roughly $250 million in annual pre-tax savings, and 1999 capital spending is expected to fall about 10 percent. Management guides to 4 to 5 percent local-currency sales growth in 1999 and says it expects earnings growth to resume, though it cautions that the economic turmoil in various regions is hard to predict. The key investor risk is the breast implant litigation. 3M has accrued $137 million in remaining liabilities against a minimum probable total of about $1.1 billion, while carrying $767 million in insurance receivables that are substantially contested by carriers. The outcome of the Minnesota occurrence-insurance litigation could materially affect future earnings. The company also raised its quarterly dividend to $0.56 (an annual rate of $2.24), extending a 41-year streak of annual increases, and it approved a repurchase of up to 12 million shares.
Feb 12, 1999
1997-A
3M CO Annual Report (Amendment), Year Ended Dec 31, 1997
This is an amendment (Form 10-K/A) to 3M's annual report for the year ended December 31, 1997, filed on March 27, 1998. It does not contain new operating results, income statement, balance sheet, or cash flow data. Its stated purpose is to add restated Financial Data Schedules (Exhibits 27.1, 27.2, and 27.3) for the 1997 interim periods, the 1996 year and interim periods, and the 1995 year. The restatements were required by SFAS No. 128, Earnings per Share, which required retroactive restatement of EPS data. The amendment says the original Form 10-K was filed on March 10, 1998, while the filing date given for this document is March 27, 1998. The excerpt provides market context. The aggregate market value of voting stock held by nonaffiliates was about $33.7 billion, based on a closing price of $83.50 per share on the NYSE on January 30, 1998. Shares outstanding were 404,042,820 as of January 31, 1998. The company's common stock is also listed on the Pacific, Chicago, Amsterdam, Swiss, and Tokyo exchanges. For investors, the key takeaway is that this filing is administrative rather than substantive. Investors seeking 3M's 1997 revenue, earnings, segment performance, or balance sheet should review the original 10-K filed on March 10, 1998, along with the restated EPS figures in the new financial data schedules.
Mar 27, 1998
1997
3M CO Annual Report, Year Ended Dec 31, 1997
3M's 1997 10-K shows a company with solid operating momentum: net sales rose 5.9% to $15.07 billion, operating income grew 7.4% to $2.675 billion, and worldwide volume rose 11%, with U.S. volume up 9% and international volume up 13%. Reported net income of $2.121 billion ($5.14 basic EPS) was inflated by an $803 million pre-tax gain on the August 1997 sale of National Advertising Company. Excluding that gain, net income was $1.626 billion, or $3.94 per basic share, and per-share earnings rose about 8.5% versus 1996. Currency translation was a meaningful drag, reducing income from continuing operations by an estimated $112 million, or 27 cents per share, and management guided that a strong dollar could cut 1998 EPS by more than 25 cents. The balance sheet and capital allocation shifted noticeably. Total debt rose to $2.514 billion from $1.968 billion, lifting debt to 30% of total capital from 24%. Management used proceeds from the divestiture and new borrowing to repurchase $1.693 billion of stock in 1997 and plans to reduce shares outstanding to about 390 million by year-end 1998. Moody's and S&P both downgraded 3M's debt ratings (to Aa1 and AA) in February 1998, citing this rising leverage. Cash flow from continuing operations fell to $1.818 billion from $2.041 billion, partly due to $308 million of taxes on the divestiture gain. The most significant risk flagged for investors is the breast implant litigation. 3M faced 7,547 lawsuits and 285 claims covering 26,193 claimants, has paid $162 million into a court-administered settlement fund, and carries $292 million in accrued liabilities. It also holds $666 million in insurance receivables, substantially all of which insurers contest, and the outcome of Minnesota coverage litigation could materially affect those recoveries. Management believes insurance coverage is sufficient to cover current exposure, but it acknowledges that future charges could hit quarterly net income.
Mar 10, 1998
1996
3M CO Annual Report, Year Ended Dec 31, 1996
3M's 1996 10-K shows a company at a strong operating peak, with continuing-operations net sales up 5.8% to $14.236 billion and operating income up 12.2% to $2.491 billion, helped by volume growth of 8% and a 1% price increase despite roughly 3 points of currency translation drag. Income from continuing operations rose 16% to $1.516 billion, or $3.63 per share, and reported net income was $1.526 billion, or $3.65 per share. Return on average stockholders' equity reached 24.4%, and management guided to solid sales and earnings growth in 1997 and a 1997–1999 aim of roughly 10% annual sales growth, 12–13% operating income growth, and 13–14% EPS growth. The central investor issue is the breast implant litigation. As of December 31, 1996, 3M faced 6,715 suits covering 21,431 claimants. The company has accrued $466 million against a minimum probable liability of about $991 million, and it carries $864 million in insurance recovery receivables. Those receivables depend on the outcome of coverage litigation in Minnesota and Texas, where insurers dispute trigger and allocation. Management says the exposure is substantially covered and that any additional charges would not have a material effect on financial position or annual results, though a charge could hit a single quarter's net income materially. The balance sheet is solid, with AAA/Aaa long-term ratings, a current ratio of 1.7, and total debt of $1.968 billion, or 24% of capital. Cash flow from continuing operations was $2.041 billion against capital spending of $1.109 billion, and the dividend was raised 10.4% to an annualized $2.12. The Imation Corp. spin-off, a $1.008 billion reduction in retained earnings, and the 1995 audio and video exit mean reported results are not fully comparable to prior periods, so investors should focus on continuing-operations figures.
Mar 11, 1997
1993-A2
3M CO Annual Report (Amendment), Year Ended Dec 31, 1993
3M Company's 1993 results show modest top-line growth and stronger earnings per share, driven largely by share repurchases and a lower share count. Net sales rose 1.0% to $14.02 billion from $13.88 billion, and net income increased 2.4% to $1.263 billion. Earnings per share rose 3.4% to $5.82 from $5.63. Operating income fell 1.9% to $1.956 billion, but that comparison is distorted by 1992 one-time items. Excluding the 1992 $129 million legal settlement gain and the $115 million special charges, 1992 operating income was about $1.980 billion, so the underlying decline was roughly 1.2%. Cost of goods sold grew faster than sales (2.2% versus 1.0%), which compressed gross margin, and SG&A declined slightly. Cash generation weakened in 1993. Operating cash flow fell 8% to $2.091 billion, mainly due to higher receivables and inventory build. Capital expenditures dropped 16% to $1.112 billion, which helped preserve free cash flow. Management directed substantial cash to shareholders: dividends rose to $3.32 per share ($721 million), and treasury stock purchases surged to $706 million from $247 million. Stockholders' equity declined slightly to $6.512 billion from $6.599 billion, reflecting the buybacks. Balance sheet leverage remains low, with total debt of about $1.49 billion against total assets of $12.2 billion. The company announced a two-for-one stock split, to be distributed on or about April 8, 1994, to holders of record on March 15, 1994. Coopers & Lybrand issued an unqualified opinion. The filing reports that 1992 accounting changes (SFAS 106 and 109) and the change in the international companies' reporting period had no material impact on 1992 results. Investors should note that share count figures in this filing are pre-split. Market value of non-affiliate equity was $23.0 billion at $107.25 per share on January 31, 1994.
Mar 11, 1994
1993-A
3M CO Annual Report (Amendment), Year Ended Dec 31, 1993
3M's 1993 annual report shows modest top-line growth and steady earnings. Net sales rose 1.0% to $14.02 billion, and net income increased 2.4% to $1.263 billion, or $5.82 per share (up 3.4% from $5.63). Operating income fell 1.9% to $1.956 billion, so the earnings gain came mainly from higher investment and other income ($96 million versus $29 million) and lower interest expense ($50 million versus $76 million), not from core operations. The 1992 results included a $129 million legal settlement gain and $115 million of special charges, which together added roughly $9 million to that year's net income. The company is also in a stronger position on shareholder returns: dividends per share rose to $3.32 from $3.20, and share repurchases more than doubled to $706 million. A two-for-one stock split was announced for distribution around April 8, 1994, to holders of record on March 15, 1994. The balance sheet remains conservative but shows some pressure. Cash fell to $274 million, and total debt (short-term plus long-term) rose to about $1.49 billion from $1.43 billion. Stockholders' equity declined slightly to $6.51 billion, reflecting the large buyback and dividend payments that exceeded earnings retention. Operating cash flow declined to $2.09 billion from $2.28 billion, mainly because of higher receivables and inventories, while capital expenditures fell to $1.11 billion from $1.32 billion. Free cash flow therefore improved to roughly $0.98 billion from $0.96 billion, and the company funded its shareholder returns with cash on hand and borrowings. Sector performance was mixed. Industrial and Consumer sales grew 2.6% and operating income rose to $849 million. Imaging and Electronic operating income increased to $271 million from $238 million on flat sales. Life Sciences sales grew 2.6%, but operating income fell to $846 million from $926 million. Asia Pacific sales rose about 17% to $2.15 billion, while Europe grew about 10% to $3.65 billion, and U.S. sales rose about 3% to $7.13 billion. Effective tax rate was stable at 35.3%, and research and development spending reached $1.03 billion, about 7.3% of sales.
Mar 11, 1994
1993
3M CO Annual Report, Year Ended Dec 31, 1993
3M's 1993 10-K shows a company navigating a difficult year with modest top-line growth but flat-to-down profitability. Worldwide net sales rose only 1.0% to $14.02 billion, with U.S. sales up about 3% to $7.13 billion while international sales fell about 1% to $6.89 billion, as currency translation (roughly -6% internationally) and price pressure (roughly -2%) offset volume gains of 6%. Operating income fell 1.9% to $1.956 billion, and the operating margin slipped to 14.0% from 14.4%. Net income rose 2.5% to $1.263 billion, or $5.82 per share, but this gain was helped by a $36 million tax-settlement benefit and other non-recurring items in investment income. Management estimates the stronger U.S. dollar cut 1993 net income by about $62 million, or 29 cents per share. Balance sheet and cash flow remained conservative. Total assets were $12.2 billion, long-term debt was $796 million, and total debt equaled 23% of stockholders' equity, with AAA long-term ratings maintained. Operating cash flow was $2.09 billion, which covered $1.11 billion of capital expenditures and $721 million of dividends. Capital spending fell 9.3%, and the company repurchased $706 million of stock. Management highlighted several headwinds for 1994, including continued price competition in the Information, Imaging and Electronic sector, currency risk, and uncertainty over U.S. health care reform affecting Life Sciences. Management also reported that the company announced a 6% dividend increase to 88 cents quarterly, a two-for-one stock split effective around April 1994, and a new authorization to repurchase up to 12 million pre-split shares. The principal risk flagged in the filing is litigation over silicone gel mammary implants. As of December 31, 1993, 3M was named in 3,054 claims and lawsuits covering 8,842 claimants. 3M was not included in the February 1994 global settlement announced by other defendants, and management says it is in discussions with plaintiffs' representatives. Management also states that its general counsel has opined that insurance coverage is sufficient, and no insurers have denied coverage, so the company believes the matter will not pose a material risk to its financial position. Environmental liabilities are also a continuing exposure, though management says these are accrued and reviewed quarterly.
Mar 7, 1994
1993
3M CO Annual Report, Year Ended Dec 31, 1993
3M's 1993 Form 10-K shows a company that grew modestly in a difficult year. Worldwide net sales rose 1.0% to $14.02 billion, with U.S. sales up about 3% and international sales down about 1% (the stronger dollar and currency translation cut international results by roughly 6 points). Net income rose 2.5% to $1.263 billion, or $5.82 per share, and operating income fell 1.9% to $1.956 billion as negative currency effects and pricing pressure offset volume gains. Management cited a challenging environment: recessions in Europe and Japan, a soft U.S. health care market, and intense price competition, particularly in memory technologies. Return on average stockholders' equity was 19.1%, and more than 25% of sales came from products introduced in the prior four years. Capital discipline and shareholder returns were central to the year. Capital expenditures fell 9.3% to $1.112 billion, while operating cash flow was $2.091 billion. Dividends rose 3.8% to $3.32 per share, and share repurchases reached $706 million. In February 1994 the board raised the quarterly dividend 6% to 88 cents, declared a two-for-one stock split (distribution around April 8, 1994), and authorized repurchase of up to 12 million pre-split shares. The company's AAA long-term ratings and 78 consecutive years of dividend payments underscore its balance sheet strength. The principal risk flagged for investors is litigation. 3M was named in 3,054 silicone gel mammary implant claims covering 8,842 individual claimants. The company was excluded from the February 1994 global settlement among other defendants and is negotiating separately. Management's general counsel opined that insurance coverage appears sufficient and no insurers had denied coverage, so management believes these matters will not be material to financial position or results. Environmental liabilities are also described as uncertain, with accruals reviewed quarterly.
Mar 7, 1994